Skip to content

Multimodal Magnetic Resonance Imaging Combined with Radiomics in Clinical Decision-Making to Reduce the Rate of Invasive Lung Biopsy in Patients with Interstitial Lung Disease: A PROTOCOL OF Single-Center Randomized Controlled Trial (RAD-ILD Trial)

Study on the value of multimodal magnetic resonance imaging combined with radiomics in distinguishing between common and non-specific interstitial pneumonia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118068
Enrollment
Unknown
Registered
2026-02-02
Start date
2026-02-02
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Pneumonia

Interventions

Control group :MDT makes decisions based on routine clinical information
Intervention group:In addition to all the information provided to the control group, provide the MDT with standardized multimodal MRI radiomics reports.

Sponsors

Guilin Medical University Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Adults aged >=18 years with a clinical suspicion of interstitial lung disease (ILD) requiring diagnostic evaluation. 2.Chest high-resolution computed tomography (HRCT) findings classified as either a "Possible UIP" or "Indeterminate for UIP" pattern according to the 2022 ATS/ERS/JRS/ALAT guidelines. 3.Cases where the multidisciplinary team (MDT) determines that a definitive diagnosis cannot be reached without further investigation, thereby warranting consideration for lung biopsy. 4.Ability to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1.Pre-existing, histopathologically confirmed diagnosis of ILD. 2. Lung biopsy (transbronchial or surgical) performed within 30 days prior to enrollment. 3. Contraindications to MRI, including but not limited to incompatible pacemakers, metallic implants, or severe claustrophobia. 4. Presence of severe comorbidities that, in the judgment of the investigator, would confer an unacceptably high risk for anesthesia or lung biopsy.

Design outcomes

Primary

MeasureTime frame
Proportion undergoing invasive lung biopsy within 90 days;

Secondary

MeasureTime frame
Time to reach a definitive diagnosis;

Countries

China

Contacts

Public ContactZhipeng Zhou

Guilin Medical University Affiliated Hospital

bigbird_zhou@126.com+86 159 0773 8260

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026